Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone reflects strong support and interest in the study's findings, with posts referencing specific elements like the comparable improvements in visual acuity and the potential for longer dosage intervals, supported by mentions of infographics, video summaries, and clinical trial details. The words and tone suggest a positive reception and recognition of the study's potential influence on treatment practices in ophthalmology.
Most discussions emphasize the positive findings of the ALTAIR study, supporting the effectiveness and safety of the treatment regimen.
Posts show high curiosity and enthusiasm about the study, with references to infographic summaries, video abstracts, and treatment comparisons.
Participants reference detailed aspects like dosage intervals, safety profiles, and implications for treatment burden, indicating moderate active engagement.
The discussions highlight the significance of the research, suggesting impacts on treatment protocols and patient outcomes, especially with mentions of reduced treatment burden and inflammation.
Ophthopedia Update: Infographic: Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: ALTAIR study https://t.co/JIdtFchFr6 #Ophthalmology #Eye #Ophthotwitter https://t.co/NGQocwgukf
#eylea has less anti drug antibodies than #beovu and less inflammation figures. Dosage interval could be comparable, as altair study suggests. https://t.co/HxriqzweIk https://t.co/NsFleaSlF0
RT @AdvancesTherapy: The results from the ALTAIR study have just been published - investigating the efficacy and safety of intravitreal #af…
The results of the ALTAIR study were published in our sister journal Advances in Therapy. Read the full article #openaccess here: https://t.co/ax1u5fQpJ0 https://t.co/WYpLQ6wYEy
The published study can be found here: https://t.co/QkUvFfnaL4 #openaccess https://t.co/A0hdP6b4rl
The results from the ALTAIR study have just been published - investigating the efficacy and safety of intravitreal #aflibercept treat-and-extend regimens in exudative age-related macular degeneration: https://t.co/EN6utdzml5 #ophthalmology https://t.co/5WcAz2JFqN
This study demonstrates that intravitreal aflibercept using treat-and-extend regimens is effective and safe for exudative age-related macular degeneration, with patients maintaining extended treatment intervals and…
RT @ophthopedia: Ophthopedia Update: Infographic: Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative ag…
RT @ophthopedia: Ophthopedia Update: Infographic: Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative ag…
RT @ophthopedia: Ophthopedia Update: Infographic: Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative ag…
Ophthopedia Update: Infographic: Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: ALTAIR study https://t.co/JIdtFchFr6 #Ophthalmology #Eye #Ophthotwitter https://t.co/NGQocwgukf
We've just published a video abstract to accompany the ALTAIR study in @AdvancesTherapy. The 4 minute video can be watched here: https://t.co/5pFaUxozvt #openaccess #videoabstract #digital https://t.co/A1F2JTjUwj
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR https://t.co/xoVyJHeS4L #clinicalresearch #clinicaltrials #endpointadjudication #electronichealthrecords #clinicalstudy https://t.co/iaIowd3LIh
RT @AdvancesTherapy: The results from the ALTAIR study have just been published - investigating the efficacy and safety of intravitreal #af…
RT @chaperonycon: #eylea has less anti drug antibodies than #beovu and less inflammation figures. Dosage interval could be comparable, as a…
RT @chaperonycon: #eylea has less anti drug antibodies than #beovu and less inflammation figures. Dosage interval could be comparable, as a…
#eylea has less anti drug antibodies than #beovu and less inflammation figures. Dosage interval could be comparable, as altair study suggests. https://t.co/HxriqzweIk https://t.co/NsFleaSlF0
#eylea 12 week dosage interval possible for more than 50% of patients. #Novartis #beovu apparently not alone in the leading position concerning treatment burden. #wetamd https://t.co/HxriqzweIk
The results of the ALTAIR study were published in our sister journal Advances in Therapy. Read the full article #openaccess here: https://t.co/ax1u5fQpJ0 https://t.co/WYpLQ6wYEy
RT @AdvancesTherapy: The published study can be found here: https://t.co/QkUvFfnaL4 #openaccess https://t.co/A0hdP6b4rl
The published study can be found here: https://t.co/QkUvFfnaL4 #openaccess https://t.co/A0hdP6b4rl
The results from the ALTAIR study have just been published - investigating the efficacy and safety of intravitreal #aflibercept treat-and-extend regimens in exudative age-related macular degeneration: https://t.co/EN6utdzml5 #ophthalmology https://t.co/5WcAz2JFqN
doi:10.1007/s12325-020-01236-x. Newsletter. Join thousands of clinicians staying current on new therapies, trial data, and expert insights ...
doi:10.1007/s40123-023-00850-6; Ohji M, Takahashi K, Okada AA, et al ... doi:10.1007/s12325-020-01236-x. Advertisement. Related Videos.
O
S
KP
OT
AT
DS
DS
D
EG
MZ
A